mouse recombinant ngf  (R&D Systems)

Journal: Cornea

Article Title: Topical Hepatocyte Growth Factor Accelerates Wound Healing and Inhibits Scarring in Experimental Corneal Injury

doi: 10.1097/ICO.0000000000003932

Figure Lengend Snippet: Efficacy of mHGF versus mNGF treatments in accelerating corneal epithelial wound closure. (A) Representative corneal fluorescein images on day 4 after injury and (B) Kaplan–Meier survival curve analysis showing percentage of corneas with epithelial defect from day 0 to day 7. N = 8 to 10 mice/group.

Article Snippet: Topical ocular treatments included PBS alone and 0.1% mNGF (murine recombinant nerve growth factor), 0.1% mHGF (murine recombinant hepatocyte growth factor), and 0.1% and 0.2% deleted HGF (dHGF) (a deleted variant of recombinant human hepatocyte growth factor), each formulated in PBS. mHGF (cat# 2207-HG/CF) and mNGF (cat# 1156-NG-100/CF) were obtained from RnD Systems, while dHGF was obtained from Kringle Pharma.

Techniques:

Journal: Cornea

Article Title: Topical Hepatocyte Growth Factor Accelerates Wound Healing and Inhibits Scarring in Experimental Corneal Injury

doi: 10.1097/ICO.0000000000003932

Figure Lengend Snippet: Efficacy of mHGF versus mNGF treatments in inhibiting corneal scar formation. (A) Representative bright-field images showing corneal scars and (B) mean scar sizes on day 7 after injury. Error bars represent standard error of the mean. N = 8 to 10 mice/group.

Article Snippet: Topical ocular treatments included PBS alone and 0.1% mNGF (murine recombinant nerve growth factor), 0.1% mHGF (murine recombinant hepatocyte growth factor), and 0.1% and 0.2% deleted HGF (dHGF) (a deleted variant of recombinant human hepatocyte growth factor), each formulated in PBS. mHGF (cat# 2207-HG/CF) and mNGF (cat# 1156-NG-100/CF) were obtained from RnD Systems, while dHGF was obtained from Kringle Pharma.

Techniques:

Journal: Cornea

Article Title: Topical Hepatocyte Growth Factor Accelerates Wound Healing and Inhibits Scarring in Experimental Corneal Injury

doi: 10.1097/ICO.0000000000003932

Figure Lengend Snippet: Regression of preexisting corneal scar with topical human recombinant HGF (0.1% and 0.2% dHGF) and 0.1% mHGF compared with 0.1% mNGF and PBS (control). (A) Representative images of scars on day 10 (top panel) and day 21 (lower panel) for each treatment group. (B) Mean percent reduction in preexisting corneal scars from day 8 (baseline) to day 21 or each treatment group. Error bars represent standard error of the mean. N = 8 to 10 mice/group.

Article Snippet: Topical ocular treatments included PBS alone and 0.1% mNGF (murine recombinant nerve growth factor), 0.1% mHGF (murine recombinant hepatocyte growth factor), and 0.1% and 0.2% deleted HGF (dHGF) (a deleted variant of recombinant human hepatocyte growth factor), each formulated in PBS. mHGF (cat# 2207-HG/CF) and mNGF (cat# 1156-NG-100/CF) were obtained from RnD Systems, while dHGF was obtained from Kringle Pharma.

Techniques: Recombinant, Control

Journal: bioRxiv

Article Title: NERVE GROWTH FACTOR IS SUFFICIENT TO CAUSE MULTIPLE OSTEOARTHRITIS-RELEVANT PATHOLOGICAL FEATURES IN NAÏVE MURINE KNEE JOINTS

doi: 10.1101/2025.06.20.660696

Figure Lengend Snippet: (A) Cartilage degeneration scores and representative histological images of knee sections from WT mice injected with vehicle, low NGF or high NGF, respectively; (B) Small chondrophytes or pre-osteophytes developed on the medial side. The graph shows the width in µm with representative histological images of wild-type (WT) mice injected with vehicle (5 µL, 2x/week), low NGF (50 ng, 5 µL, 2x/week), or high NGF (500 ng, 5 µL, 2x/week) for 4 weeks, n=5 mice/group. Black insets in B showing examples of developing pre-osteophytes in low dose and high dose NGF groups; (C-F) Bone volume / Trabecular volume (BV/TV) ratio, bone mineral density (BMD, in mm), mean trabecular thickness (Tb.Th, in mm), mean trabecular separation (Tb.Sp, in mm) respectively in the medial and lateral tibial subchondral trabecular bone from knees injected with NGF (500ng, n=6) or Vehicle (n=4); (G) Representative µCT scans of the subchondral trabecular bone from vehicle and NGF groups, respectively. For A and B, we used two-way ANOVA with Sidak’s post-test. For C-F, we used unpaired two-tailed t test. Scale bar=100µm.

Article Snippet: In Experiment 1, NGF (R&D systems, # 1156-NG-100), 50ng or 500ng in 5 μL, or vehicle control (0.1% BSA) (05470, Sigma) (n=5 mice/group) were injected IA into the right knee joint of naive 12-week-old male WT mice, twice a week for 4 weeks.

Techniques: Injection, Two Tailed Test